Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC
Phase 2 Withdrawn
PRISM
Phase 2 Withdrawn
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
Phase 2 Withdrawn
HPV
Phase 2 Withdrawn
XACT-PANC-2
Phase 2 Withdrawn
Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy
Phase 2 Withdrawn
S-1 and Radiotherapy for Elderly Esophageal Cancer Patients
Phase 2 Withdrawn
Abscopal Effect for Metastatic Colorectal Cancer
Phase 2 Withdrawn
APX005M
Phase 2 Withdrawn
Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
Phase 2 Withdrawn
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC
Phase 2 Withdrawn
Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women
Phase 2 Withdrawn
EURO-DIGNITY
Phase 2 Withdrawn
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
Phase 2 Withdrawn
Trial of BMX-001 or Placebo in Head and Neck Cancer Patients
Phase 2 Withdrawn
Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.
Phase 2 Withdrawn
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
Phase 2 Withdrawn
Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer
Phase 2 Withdrawn
Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma
Phase 2 Withdrawn
Panc-Durval+RT
Phase 2 Withdrawn
Abscopal Effect for Metastatic Small Cell Lung Cancer
Phase 2 Withdrawn
Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer
Phase 2 Withdrawn
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
Phase 2 Withdrawn
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
Phase 2 Withdrawn
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Phase 2 Withdrawn
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Phase 2 Withdrawn
Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer
Phase 2 Withdrawn
Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer
Phase 2 Withdrawn
SA02
Phase 2 Withdrawn
Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer
Phase 2 Withdrawn
A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer
Phase 2 Withdrawn
Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma
Phase 2 Withdrawn
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
Phase 2 Withdrawn
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Phase 2 Withdrawn
S9715, Chemotherapy and Radiation Therapy in Treating Patients With Advanced Cancer of the Nasopharynx
Phase 2 Withdrawn
Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Withdrawn
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
Phase 2 Withdrawn
Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)
Phase 2 Withdrawn
RTANDTACE
Phase 2 Withdrawn
Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer
Phase 2 Withdrawn
Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma
Phase 2 Withdrawn
S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum
Phase 2 Withdrawn
Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase 2 Withdrawn
Palliative Treatment of Ulcerated Cutaneous Metastases: Trial Between Electrochemotherapy and Radiotherapy
Phase 2 Withdrawn
98 enrolled
Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma
Phase 2 Withdrawn
450 enrolled
Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
Phase 2 Withdrawn
28 enrolled